Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
4d
Zacks Investment Research on MSNEC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
Adjuvant therapy with nivolumab (Opdivo, “nivo”) continues to show disease-free survival (DFS) and overall survival (OS) benefits compared with placebo among patients with muscle-invasive ...
In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...
Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...
A doctor or nurse gives the injections using a special needle free device. The SCIB1 or iSCIB+ enters the skin at high pressure and reaches the muscle. The team can tell you more about this. You have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results